As already informed to the exchange, Bal Pharma has informed that the Board of Directors of the Company met on 14/11/2019 and approved the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30/09/2019, which was subjected to limited review by the statutory auditors of the Company. Certified copy of the unaudited financial results along with the copy of the limited review report issued by the statutory auditors is enclosed with this letter for submission to the Exchange; and appointed G.Rengarajan as Chief Financial Officer (CFO) of the Company in place of Chaitanya A.N.V.K, who has resigned citing personal reasons. G. Rengarajan is a Cost and Management Accountant (CMA) from ICWAI with over 20 years of experience in the fields of finance and accounts from various prominent Companies. The Board meeting commenced at 5 PM and concluded at 9 PM on 14.11.2019.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: